Financial overview
Five-year overview summary
Always refer to the electronic version of the ASML Annual Reports based on US GAAP for the full and official financial information.
Income statement Year ended December 31 (€, in millions, except per share data) | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net sales | 11, 820.0 | 13,978.5 | 18,611.0 | 21,173.4 | 27,558.5 |
Gross profit | 5,279.8 | 6,797.2 | 9,809.0 | 10,700.1 | 14,136.1 |
Research and development costs | (1,968.5) | (2,200.8) | (2,547.0) | (3,253.5) | (3,980.6) |
Selling, general and administrative costs | (520.5) | (544.9) | (725.6) | (945.9) | (1,113.2) |
Other income | - | - | 213.7 | - | - |
Income from operations | 2,790.8 | 4,051.5 | 6,750.1 | 6,500.7 | 9,042.3 |
Net income | 2,592.3 | 3,553.7 | 5,883.2 | 5,624.2 | 7,839.0 |
Gross profit as a percentage of net sales | 44.7% | 48.6% | 52.7% | 50.5% | 51.3% |
Income from operations as a percentage of net sales | 23.6% | 29.0% | 36.3% | 30.7% | 32.8% |
Basic net income per share | 6.16 | 8.49 | 14.36 | 14.14 | 19.91 |
Diluted net income per share | 6.15 | 8.48 | 14.34 | 14.13 | 19.89 |
Number of ordinary shares used in computing per share amounts: | |||||
Basic | 420.8 | 418.3 | 409.8 | 397.7 | 393.8 |
Diluted | 421.6 | 419.1 | 410.4 | 398.0 | 394.1 |
Balance sheet as of December 31 (€, in millions) |
2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Cash and cash equivalents | 3,532.3 | 6,049.4 | 6,951.8 | 7,268.3 | 7,004.7 |
Short-term investments | 1,185.8 | 1,302.2 | 638.5 | 107.7 | 5.4 |
Total assets | 22,629.6 | 27,267.4 | 30,231.0 | 36,300.4 | 39,957.5 |
Long-term debt (current and non – current) | 3,108.3 | 4,678.2 | 4,584.1 | 4,260.4 | 4,631.6 |
Shareholders' equity | 12,592.2 | 13,865.4 | 10,140.6 | 8,810.8 | 13,452.4 |
Employees as of December 31 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Number of payroll employees (in FTEs) | 23,219 | 26,614 | 29,861 | 36,112 | 40,309 |